IMNM News and Press, Immunome Inc. From 02/06/24

– AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile – Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome management will present at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference on Thursday, Febr...

2024-01-18 15:30:11 ET Summary Immunome has experienced a meteoric rise in market capitalization without any pipeline drugs reaching clinical trials. The company's pipeline includes IM-1021, an antibody-drug conjugate targeting ROR1, and IM-4320, a monoclonal antibody targeting IL...

2024-01-09 03:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

- Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs - - Zentalis to receive up-front payment of $35 million in cash and Immunome comm...

2024-01-04 08:29:43 ET More on Immunome Immunome a new outperform at Wedbush on cancer platforms Seeking Alpha’s Quant Rating on Immunome Historical earnings data for Immunome Financial information for Immunome For further details see: Immu...

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer. Mr. Roberts has over three decades of experience in product development, global m...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Thursday, Jan...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity...

2023-12-26 08:47:34 ET More on Atreca, Immunome, etc. Immunome: The Morphimmune Merger And The Pipeline Immunome a new outperform at Wedbush on cancer platforms Seeking Alpha’s Quant Rating on Atreca Historical earnings data for Atreca Financia...